Climb Bio Valuation
| CLYM Stock | 1.95 0.08 3.94% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. Climb Bio shows a prevailing Real Value of USD1.87 per share. The current price of the firm is USD1.95. Our model approximates the value of Climb Bio from analyzing the firm fundamentals such as Number Of Employees of 9, net income of (35.12 M), and Net Asset of 110.47 M as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Climb Bio's price fluctuation is dangerous at this time. Calculation of the real value of Climb Bio is based on 3 months time horizon. Increasing Climb Bio's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Climb stock is determined by what a typical buyer is willing to pay for full or partial control of Climb Bio. Since Climb Bio is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Climb Stock. However, Climb Bio's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.95 | Real 1.87 | Hype 2.43 | Naive 1.41 |
The intrinsic value of Climb Bio's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Climb Bio's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Climb Bio helps investors to forecast how Climb stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Climb Bio more accurately as focusing exclusively on Climb Bio's fundamentals will not take into account other important factors: Climb Bio Cash |
|
Climb Bio Total Value Analysis
Climb Bio is currently anticipated to have valuation of 0 with market capitalization of 0, debt of 2.87 M, and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Climb Bio fundamentals before making equity appraisal based on enterprise value of the companyClimb Bio Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The recent return on assets of Climb suggests not a very effective usage of assets in December.Climb Bio Profitability Analysis
Net Loss for the year was (35.12 M) with profit before overhead, payroll, taxes, and interest of 0.About Climb Bio Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Climb Bio. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Climb Bio based exclusively on its fundamental and basic technical indicators. By analyzing Climb Bio's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Climb Bio's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Climb Bio. We calculate exposure to Climb Bio's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Climb Bio's related companies.Climb Bio Growth Indicators
Investing in growth stocks can be very risky. If the company such as Climb Bio does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 27.7 M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Climb Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Climb Bio. If investors know Climb will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Climb Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Climb Bio is measured differently than its book value, which is the value of Climb that is recorded on the company's balance sheet. Investors also form their own opinion of Climb Bio's value that differs from its market value or its book value, called intrinsic value, which is Climb Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Climb Bio's market value can be influenced by many factors that don't directly affect Climb Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Climb Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Climb Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Climb Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.